These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31447275)

  • 21. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
    Manwani R; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Yong K; Rabin N; Popat R; Kyriakou C; Worthington S; Sharpley F; Smith M; Shah R; Cheesman S; Hawkins PN; Wechalekar AD
    Br J Haematol; 2019 Dec; 187(5):638-641. PubMed ID: 31388995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib-dexamethasone versus high-dose melphalan for Japanese patients with systemic light-chain (AL) amyloidosis: a retrospective single-center study.
    Katoh N; Ueno A; Yoshida T; Tazawa KI; Shimojima Y; Gono T; Sekijima Y; Matsuda M; Ikeda SI
    Int J Hematol; 2017 Mar; 105(3):341-348. PubMed ID: 27832515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recommendations for the treatment of AL amyloidosis].
    Brulc EB; Carretero M; Aguirre MA; Negro A; Ulacia MD; Perez de Arenaza D; Villanueva E; Sáez MS; Sorroche P; Posadas Martínez ML; Nucifora EM
    Medicina (B Aires); 2022; 82(4):591-604. PubMed ID: 35904916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.
    Cornell RF; Zhong X; Arce-Lara C; Atallah E; Blust L; Drobyski WR; Fenske TS; Pasquini MC; Rizzo JD; Saber W; Hari PN
    Bone Marrow Transplant; 2015 Jul; 50(7):914-7. PubMed ID: 25915809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease.
    Brunger AF; Nienhuis HLA; Bijzet J; Roeloffzen WWH; Vellenga E; Hazenberg BPC
    Amyloid; 2020 Jun; 27(2):119-127. PubMed ID: 32052655
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
    Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
    Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis.
    Sharpley FA; De-Silva D; Mahmood S; Sachchithanantham S; Ramsay I; Garcia Mingo A; Worthington S; Hughes D; Mehta A; Kyriakou C; Griffiths PD; Wechalekar AD
    Eur J Haematol; 2020 Mar; 104(3):230-235. PubMed ID: 31815313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclophosphamide + Thalidomide + Dexamethasone Versus Melphalan + Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients.
    Liu B; Wang Y; Bai M; Wang D; Zhao J; Zhang M; Sun S
    Clin Ther; 2019 Jun; 41(6):1186-1198. PubMed ID: 30718006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.
    Minnema MC; Nasserinejad K; Hazenberg B; Hegenbart U; Vlummens P; Ypma PF; Kröger N; Wu KL; Kersten MJ; Schaafsma MR; Croockewit S; de Waal E; Zweegman S; Tick L; Broijl A; Koene H; Bos G; Sonneveld P; Schönland S
    Haematologica; 2019 Nov; 104(11):2274-2282. PubMed ID: 30923094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation.
    Abdallah M; Sanchorawala V
    Am J Med; 2022 Apr; 135 Suppl 1():S30-S37. PubMed ID: 35081382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
    Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of relapse after upfront bortezomib therapy in AL amyloidosis.
    Basset M; Milani P; Russo F; Lavatelli F; Nuvolone M; Foli A; Perlini S; Palladini G; Merlini G
    Amyloid; 2017 Mar; 24(sup1):60-61. PubMed ID: 28434342
    [No Abstract]   [Full Text] [Related]  

  • 34. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.
    Palladini G; Milani P; Foli A; Basset M; Russo F; Perlini S; Merlini G
    Blood; 2018 Feb; 131(5):525-532. PubMed ID: 29101236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
    Lamm W; Willenbacher W; Lang A; Zojer N; Müldür E; Ludwig H; Schauer-Stalzer B; Zielinski CC; Drach J
    Ann Hematol; 2011 Feb; 90(2):201-6. PubMed ID: 20821326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
    Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
    Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
    [TBL] [Abstract][Full Text] [Related]  

  • 37.  Liver transplantation followed by autologous stem cell transplantation for acute liver failure caused by AL amyloidosis. Case report and review of the literature.
    Elnegouly M; Specht K; Zoller H; Matevossian E; Bassermann F; Umgelter A
    Ann Hepatol; 2016; 15(4):592-7. PubMed ID: 27236160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient.
    Denman J; Manavi K; Cook M
    Int J STD AIDS; 2017 Sep; 28(10):1045-1047. PubMed ID: 28632471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Chemotherapies and Stem Cell Transplantation for Systemic AL Amyloidosis: A Network Meta-Analysis.
    Cai Y; Xu S; Li N; Li S; Xu G
    Front Pharmacol; 2019; 10():1601. PubMed ID: 32063846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary.
    Lewis E; McCulloch S; Mahe E; Bahlis N; Neri P; Tay J; Duggan P; Jimenez-Zepeda VH
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e331-e334. PubMed ID: 37532664
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.